Advertisement

Branched Short-Chain Fatty Acid Isovaleric Acid Causes Colonic Smooth Muscle Relaxation via cAMP/PKA Pathway

  • Bryan A. Blakeney
  • Molly S. Crowe
  • Sunila Mahavadi
  • Karnam S. Murthy
  • John R. GriderEmail author
Original Article
  • 52 Downloads

Abstract

Background

Isovaleric acid (IVA) is a 5-carbon branched-chain fatty acid present in fermented foods and produced in the colon by bacterial fermentation of leucine. We previously reported that the shorter, straight-chain fatty acids acetate, propionate and butyrate differentially affect colonic motility; however, the effect of branched-chain fatty acids on gut smooth muscle and motility is unknown.

Aims

To determine the effect of IVA on contractility of colonic smooth muscle.

Methods

Murine colonic segments were placed in a longitudinal orientation in organ baths in Krebs buffer and fastened to force transducers. Segments were contracted with acetylcholine (ACh), and the effects of IVA on ACh-induced contraction were measured in the absence and presence of tetrodotoxin (TTx) or inhibitors of nitric oxide synthase [L-N-nitroarginine (L-NNA)] or adenylate cyclase (SQ22536). The effect of IVA on ACh-induced contraction was also measured in isolated muscle cells in the presence or absence of SQ22536 or protein kinase A (PKA) inhibitor (H-89). Direct activation of PKA was measured in isolated muscle cells.

Results

In colonic segments, ACh-induced contraction was inhibited by IVA in a concentration-dependent fashion; the IVA response was not affected by TTx or L-NNA but inhibited by SQ22536. Similarly, in isolated colonic muscle cells, ACh-induced contraction was inhibited by IVA in a concentration-dependent fashion and the effect blocked by SQ22536 and H-89. IVA also increased PKA activity in isolated smooth muscle cells.

Conclusions

The branched-chain fatty acid IVA acts directly on colonic smooth muscle and causes muscle relaxation via the PKA pathway.

Keywords

Colon Smooth muscle Isovaleric acid Branched-chain fatty acid Cyclic AMP Adenylyl cyclase Protein kinase A SQ22536 H-89 Tetrodotoxin Nitric oxide synthase L-N-nitroarginine 

Notes

Acknowledgments

This work was supported by grants DK34153 (JR Grider) and DK28300 and DK15564 (KS Murthy) from the National Institute of Diabetes and Kidney Diseases.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Cummings JH. Short chain fatty acids in the human colon. Gut. 1981;22:763–779.CrossRefGoogle Scholar
  2. 2.
    Wong JM, de Souza R, Kendall CW, Emam A, Jenkins DJ. Colonic health: fermentation and short chain fatty acids. J Clin Gastroenterol. 2006;40:235–243.CrossRefGoogle Scholar
  3. 3.
    Cummings JH, Pomare EW, Branch WJ, Naylor CP, Macfarlane GT. Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut. 1987;28:1221–1227.CrossRefGoogle Scholar
  4. 4.
    Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell. 2016;165:1332–1345.CrossRefGoogle Scholar
  5. 5.
    Macfarlane GT, Macfarlane S. Bacteria, colonic fermentation, and gastrointestinal health. J AOAC Int. 2012;95:50–60.CrossRefGoogle Scholar
  6. 6.
    David LA, Maurice CF, Carmody RN, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014;505:559–563.CrossRefGoogle Scholar
  7. 7.
    Morrison DJ, Preston T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes. 2016;7:189–200.CrossRefGoogle Scholar
  8. 8.
    Bolognini D, Tobin AB, Milligan G, Moss CE. The pharmacology and function of receptors for short-chain fatty acids. Mol Pharmacol. 2016;89:388–398.CrossRefGoogle Scholar
  9. 9.
    Soldavini J, Kaunitz JD. Pathobiology and potential therapeutic value of intestinal short-chain fatty acids in gut inflammation and obesity. Dig Dis Sci. 2013;58:2756–2766.CrossRefGoogle Scholar
  10. 10.
    Kaji I, Kaunitz JD. Luminal chemosensing in the gastroduodenal mucosa. Curr Opin Gastroenterol. 2017;33:439–445.CrossRefGoogle Scholar
  11. 11.
    O’Keefe SJD. Diet, microorganisms and their metabolites and colon cancer. Nat Rev Gastroenterol Hepatol. 2016;13:691–706.CrossRefGoogle Scholar
  12. 12.
    Binder HJ. Role of colonic short-chain fatty acid transport in diarrhea. Annu Rev Physiol. 2010;72:297–313.CrossRefGoogle Scholar
  13. 13.
    Andriamihaja M, Davila A-M, Eklou-Lawson M, et al. Colon luminal content and epithelial cell morphology are markedly modified in rats fed with a high-protein diet. Am J Physiol Liver Physiol. 2010;299:G1030–G1037.Google Scholar
  14. 14.
    Mortensen PB, Clausen MR. Short-chain fatty acids in the human colon: relation to gastrointestinal health and disease. Scand J Gastroenterol Suppl. 1996;216:132–148.CrossRefGoogle Scholar
  15. 15.
    Russell WR, Gratz SW, Duncan SH, et al. High-protein, reduced-carbohydrate weight-loss diets promote metabolite profiles likely to be detrimental to colonic health. Am J Clin Nutr. 2011;93:1062–1072.CrossRefGoogle Scholar
  16. 16.
    Yang J, Rose DJ. Long-term dietary pattern of fecal donor correlates with butyrate production and markers of protein fermentation during in vitro fecal fermentation. Nutr Res. 2014;34:749–759.CrossRefGoogle Scholar
  17. 17.
    Ran-Ressler RR, Glahn RP, Bae S, Brenna JT. Branched-chain fatty acids in the neonatal gut and estimated dietary intake in infancy and adulthood. Nestle Nutr Inst Workshop Ser. 2013;77:133–143.CrossRefGoogle Scholar
  18. 18.
    Ran-Ressler RR, Bae S, Lawrence P, Wang DH, Brenna JT. Branched-chain fatty acid content of foods and estimated intake in the USA. Br J Nutr. 2014;112:565–572.CrossRefGoogle Scholar
  19. 19.
    Jakobsdottir G, Bjerregaard JH, Skovbjerg H, Nyman M. Fasting serum concentration of short-chain fatty acids in subjects with microscopic colitis and celiac disease: no difference compared with controls, but between genders. Scand J Gastroenterol. 2013;48:696–701.CrossRefGoogle Scholar
  20. 20.
    Vockley J, Ensenauer R. Isovaleric acidemia: new aspects of genetic and phenotypic heterogeneity. Am J Med Genet C Semin Med Genet. 2006;142C:95–103.CrossRefGoogle Scholar
  21. 21.
    Shigematsu Y, Sudo M, Momoi T, et al. Changing plasma and urinary organic acid levels in a patient with isovaleric acidemia during an attack. Pediatr Res. 1982;16:771–775.CrossRefGoogle Scholar
  22. 22.
    Weir TL, Manter DK, Sheflin AM, et al. Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. PLoS ONE. 2013;8:e70803.CrossRefGoogle Scholar
  23. 23.
    Farup PG, Rudi K, Hestad K. Faecal short-chain fatty acids—a diagnostic biomarker for irritable bowel syndrome? BMC Gastroenterol. 2016;16:51–57.CrossRefGoogle Scholar
  24. 24.
    Høverstad T, Bjørneklett A, Fausa O, Midtvedt T. Short-chain fatty acids in the small-bowel bacterial overgrowth syndrome. Scand J Gastroenterol. 1985;20:492–499.CrossRefGoogle Scholar
  25. 25.
    Høverstad T, Fausa O, Bjørneklett A, Bøhmer T. Short-chain fatty acids in the normal human feces. Scand J Gastroenterol. 1984;19:375–381.CrossRefGoogle Scholar
  26. 26.
    François IEJA, Lescroart O, Veraverbeke WS, et al. Effects of wheat bran extract containing arabinoxylan oligosaccharides on gastrointestinal parameters in healthy preadolescent children. J Ped Nutr. 2014;58:647–653.CrossRefGoogle Scholar
  27. 27.
    Karlsson C, Ahrné S, Molin G, et al. Probiotic therapy to men with incipient arteriosclerosis initiates increased bacterial diversity in colon: a randomized controlled trial. Atherosclerosis. 2010;208:228–233.CrossRefGoogle Scholar
  28. 28.
    Nilsson U, Johansson M, Nilsson Å, Björck I, Nyman M. Dietary supplementation with β-glucan enriched oat bran increases faecal concentration of carboxylic acids in healthy subjects. Eur J Clin Nutr. 2008;62:978–984.CrossRefGoogle Scholar
  29. 29.
    Grider JR, Piland BE. The peristaltic reflex induced by short-chain fatty acids is mediated by sequential release of 5-HT and neuronal CGRP but not BDNF. Am J Physiol Gastrointest Liver Physiol. 2006;292:G429–G437.CrossRefGoogle Scholar
  30. 30.
    Reigstad CS, Salmonson CE, Rainey JF, et al. Gut microbes promote colonic serotonin production through an effect of short-chain fatty acids on enterochromaffin cells. FASEB J. 2015;29:1395–1403.CrossRefGoogle Scholar
  31. 31.
    Akiba Y, Inoue T, Kaji I, et al. Short-chain fatty acid sensing in rat duodenum. J Physiol. 2015;593:585–599.CrossRefGoogle Scholar
  32. 32.
    Kaji I, Akiba Y, Konno K, et al. Neural FFA3 activation inversely regulates anion secretion evoked by nicotinic ACh receptor activation in rat proximal colon. J Physiol. 2016;594:3339–3352.CrossRefGoogle Scholar
  33. 33.
    Fukumoto S, Tatewaki M, Yamada T, et al. Short-chain fatty acids stimulate colonic transit via intraluminal 5-HT release in rats. Am J Physiol Regul Integr Comp Physiol. 2003;284:R1269–R1276.CrossRefGoogle Scholar
  34. 34.
    Bhattarai Y, Schmidt BA, Linden DR, et al. Human-derived gut microbiota modulates colonic secretion in mice by regulating 5-HT3 receptor expression via acetate production. Am J Physiol Gastrointest Liver Physiol. 2017;313:G80–G87.CrossRefGoogle Scholar
  35. 35.
    Kaji I, Akiba Y, Furuyama T, et al. Free fatty acid receptor 3 activation suppresses neurogenic motility in rat proximal colon. Neurogastroenterol Motil. 2018;30:e13157.CrossRefGoogle Scholar
  36. 36.
    Cherbut C, Aubé AC, Blottière HM, et al. In vitro contractile effects of short chain fatty acids in the rat terminal ileum. Gut. 1996;38:53–58.CrossRefGoogle Scholar
  37. 37.
    Murthy KS. Signaling for contraction and relaxation in smooth muscle of the gut. Annu Rev Physiol. 2006;68:345–374.CrossRefGoogle Scholar
  38. 38.
    Murthy KS, Jin JG, Grider JR, Makhlouf GM.  Characterization of PACAP receptors and signaling pathways in rabbit gastric muscle cells. Am J Physiol. 1997;272:G1391–G1399.PubMedGoogle Scholar
  39. 39.
    Schindelin J, Arganda-Carreras I, Frise E, et al. Fiji: an open-source platform fro biological-image analysis. Nat Methods. 2012;9:676–682.CrossRefGoogle Scholar
  40. 40.
    Bellono NW, Bayrer JR, Leitch DB, et al. Enterochromaffin cells are gut chemosensors that couple to sensory neural pathways article enterochromaffin cells are gut chemosensors that couple to sensory neural pathways. Cell. 2017;170:1–14.CrossRefGoogle Scholar
  41. 41.
    Jovancevic N, Dendorfer A, matzkies M, et al. Medium-chain fatty acids modulate myocardial function via a cardiac odorant receptor. Basic Res Cardiol. 2017;112:13–32.CrossRefGoogle Scholar
  42. 42.
    Zhong H, SuYang H, Erdjument-Bromage H, Tempst P, Ghosh S. The transcriptional activity of NF-κB is regulated by the IκB-associated PKAc subunit through a cyclic AMP–independent mechanism. Cell. 1997;89:413–424.CrossRefGoogle Scholar
  43. 43.
    Sriwai W, Mahavadi S, Al-Shboul O, Grider JR, Murthy KS. Distinctive G protein-dependent signaling by protease-activated receptor 2 (PAR2) in smooth muscle: feedback inhibition of RhoA by cAMP-independent PKA. PLoS ONE. 2013;8:e66743.CrossRefGoogle Scholar
  44. 44.
    Sriwai W, Zhou H, Murthy KS. G(q)-dependent signalling by the lysophosphatidic acid receptor LPA(3) in gastric smooth muscle: reciprocal regulation of MYPT1 phosphorylation by Rho kinase and cAMP-independent PKA. Biochem J. 2008;411:543–551.CrossRefGoogle Scholar
  45. 45.
    Elrick MM, Samson WK, Corbett JA, et al. Neuronostatin acts via GPR107 to increase cAMP-independent PKA phosphorylation and proglucagon mRNA accumulation in pancreatic α-cells. Am J Physiol Regul Integr Comp Physiol. 2016;310:R143–R155.CrossRefGoogle Scholar
  46. 46.
    Su S-F, Yang A-M, Yang S-B, et al. Intracerebroventricular administration of neuronostatin delays gastric emptying and gastrointestinal transit in mice. Peptides. 2012;35:31–35.CrossRefGoogle Scholar
  47. 47.
    Amato A, Baldassano S, Caldara G, Mulè F. Neuronostatin: peripheral site of action in mouse stomach. Peptides. 2015;64:8–13.CrossRefGoogle Scholar
  48. 48.
    Murthy KS, Zhou H, Grider JR, Makhlouf GM. Inhibition of sustained smooth muscle contraction by PKA and PKG preferentially mediated by phosphorylation of RhoA. Am J Physiol Liver Physiol. 2003;284:G1006–G1016.Google Scholar
  49. 49.
    Murthy KS, Makhlouf GM. Regulation of adenylyl cyclase type V/VI in smooth muscle: interplay of inhibitory G protein and Ca2+ influx. Mol Pharm. 1998;54:122–128.CrossRefGoogle Scholar
  50. 50.
    Kristev A, Peichev L, Zaprianov G, Lukanov J. Effect of sodium valproate on the spontaneous contractile and bioelectric activity of smooth muscle fibres isolated from experimental animals. Folia Med (Plovdiv). 1994;36:11–19.Google Scholar
  51. 51.
    Hwang SJ, O’Kane N, Singer C, et al. Block of inhibitory junction potentials and TREK-1 channels in murine colon by Ca2 + store-active drugs. J Physiol. 2008;586:1169–1184.CrossRefGoogle Scholar
  52. 52.
    Alcaino C, Farrugia G, Beyder A. Mechanosensitive piezo channels in the gastrointestinal tract. Curr Top Membr. 2017;79:219–244.CrossRefGoogle Scholar
  53. 53.
    Manville RW, Abbott GW. Ancient and modern anticonvulsants act synergistically in a KCNQ potassium channel binding pocket. Nat Commun. 2018;9:3845–3858.CrossRefGoogle Scholar
  54. 54.
    Jepps TA, Greenwood IA, Moffatt JD, Sanders KM, Ohya S. Molecular and functional characterization of Kv7 K + channel in murine gastrointestinal smooth muscles. Am J Physiol Gastrointest Liver Physiol. 2009;297:G107–G115.CrossRefGoogle Scholar
  55. 55.
    Salzer I, Erdem FA, Chen W-Q, et al. Phosphorylation regulates the sensitivity of voltage-gated Kv7.2 channels towards phosphatidylinositol-4,5-bisphosphate. J Physiol. 2017;595:759–776.CrossRefGoogle Scholar
  56. 56.
    Mani BK, Robakowski C, Brueggemann LI, et al. Kv.75 potassium channel subunits are the primary targets for PKA-dependent enhancement of vascular smooth muscle Kv7 currents. Mol Pharmacol. 2016;89:323–334.CrossRefGoogle Scholar
  57. 57.
    Kalbe B, Schlimm M, Wojcik S, et al. Olfactory signaling components and olfactory receptors are expressed in tubule cells of the human kidney. Arch Biochem Biophys. 2016;610:8–15.CrossRefGoogle Scholar
  58. 58.
    Priori D, Colombo M, Clavenzani P, et al. The olfactory receptor OR51E1 is present along the gastrointestinal tract of pigs, co-localizes with enteroendocrine cells and is modulated by intestinal microbiota. PLoS ONE. 2015;10:e0129501.CrossRefGoogle Scholar
  59. 59.
    Pluznick JL, Protzko RJ, Gevorgyan H, et al. Olfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion and blood pressure regulation. Proc Natl Acad Sci USA. 2013;110:4410–4415.CrossRefGoogle Scholar
  60. 60.
    Christensen LW, Kuhre RE, Janus C, Svendsen B, Holst JJ. Vascular, but not luminal, activation of FFAR1 (GPR40) stimulates GLP-1 secretion from isolated perfused rat small intestine. Physiol Rep. 2015;3:e12551.CrossRefGoogle Scholar
  61. 61.
    Szczesniak O, Hestad KA, Hanssen JF, Rudi K. Isovaleric acid in stool correlates with human depression. Nutr Neurosci. 2016;18:1–12.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Bryan A. Blakeney
    • 1
  • Molly S. Crowe
    • 1
  • Sunila Mahavadi
    • 1
  • Karnam S. Murthy
    • 1
  • John R. Grider
    • 1
    Email author
  1. 1.Department of Physiology and Biophysics, VCU Program in Enteric Neuromuscular SciencesVirginia Commonwealth UniversityRichmondUSA

Personalised recommendations